Monopar Therapeutics Inc. (MNPR) Stock Forecast & Price Target
Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 12, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Monopar Therapeutics Inc. (MNPR), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Monopar Therapeutics Inc., the average estimate for 2030 earnings per share is $4.84; with published estimates ranging from $2.59 to $8.03; 9 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Monopar Therapeutics Inc. (MNPR) forecast — frequently asked questions
What is the analyst price target for Monopar Therapeutics Inc.?
Analysts covering Monopar Therapeutics Inc. (MNPR) have a consensus price target of $126.00, 77.3% above the current price of $71.06. Published targets range from $105.00 to $145.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Monopar Therapeutics Inc.'s earnings?
The average analyst estimate for Monopar Therapeutics Inc. (MNPR) earnings per share in 2030 is 4.84, with individual estimates between 2.59 and 8.03.
How much revenue is Monopar Therapeutics Inc. expected to make?
Analysts forecast Monopar Therapeutics Inc. (MNPR) revenue of $282.47M in 2030, based on 5 published estimates.
How many analysts cover MNPR?
9 analysts contribute estimates for Monopar Therapeutics Inc. (MNPR). Thin coverage makes an average less reliable.
Analyst forecasts for other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.